Obbligazioni societarie HIGH YIELD e oltre, verso frontiere inesplorate - Vol. 2 (5 lettori)

captain sparrow

Forumer storico
accreditata cedola Promontoria. anche se secured il bond viaggia in area 90:(:(
e Vallourec perde ancora qualcosina. speriamo che passato agosto la situazione migliori un pochino
 

Fabrib

Forumer storico
Ciao Teva 2.95% 18dec2022, USD US88165FAG72 scese del 6,4% cosa è successo?
Teva: Maximum Pessimism - Teva Pharmaceutical Industries Limited (NYSE:TEVA) | Seeking Alpha

Questa è di ieri:
Teva Pharmaceutical Industries has come out on the short end of an appeals court ruling on three patents covering weight-loss pill Contrave (naltrexone HCl and bupropion HCl).
In a 2-1 decision, the court upheld one patent that expires in 2030 but invalidated two others that expire in 2024 and 2025. Unfortunately for Teva, it is barred from selling a generic version until all three patents have expired.
Contrave, originally marketed by Takeda (licensed from Orexigen), is now sold by Nalproprion Pharmaceuticals, a joint venture between Pernix Therapeutics Holdings and certain institutional investors.
 

Di buzzo buono

Forumer attivo
Teva: Maximum Pessimism - Teva Pharmaceutical Industries Limited (NYSE:TEVA) | Seeking Alpha

Questa è di ieri:
Teva Pharmaceutical Industries has come out on the short end of an appeals court ruling on three patents covering weight-loss pill Contrave (naltrexone HCl and bupropion HCl).
In a 2-1 decision, the court upheld one patent that expires in 2030 but invalidated two others that expire in 2024 and 2025. Unfortunately for Teva, it is barred from selling a generic version until all three patents have expired.
Contrave, originally marketed by Takeda (licensed from Orexigen), is now sold by Nalproprion Pharmaceuticals, a joint venture between Pernix Therapeutics Holdings and certain institutional investors.
grazie Fabrib per la info molto utile
 

Users who are viewing this thread

Alto